A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO-501A, AN ANTI-CD19 ALLOGENEIC CAR T CELL THERAPY, AND ALLO-647, AN ANTI-CD52 MONOCLONAL ANTIBODY, IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/95565/MonH-2023-385800(v3)
NMA SSA Reference Number: SSA/95565/MonH-2023-394189(v3)
Monash Health Local Reference: RES-23-0000-224A
StatusActive
Effective start/end date21/09/23 → 20/09/28